Schizophrenia Clinical Trial
Official title:
Music to Reduce Use of Smoking in Patients With Schizophrenia
Verified date | August 2019 |
Source | NYU Langone Health |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to explore the impact of self-selected music listening which targets disrupting the reward process maintaining smoking and additionally attenuating the reward processing deficits associated with schizophrenia. Five participants with schizophrenia/schizoaffective disorder who smoke/nicotine will participate in an individual session of self-selected music listening for a half an hour.
Status | Completed |
Enrollment | 2 |
Est. completion date | September 17, 2018 |
Est. primary completion date | September 17, 2018 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - clinician verification diagnosis of Schizophrenia or Schizoaffective Disorder - smoked at least 10 cigarettes per day for the past month - score of 4 or more on the Fagerstrom Test for Nicotine Dependence73 - psychiatric stability (e.g., no psychiatric hospitalizations within the last year, no expectation for medication change during study participation, no active suicidal ideation, no symptoms that interfere with ability to participate in study activities) - the capacity to participate in the informed consent process Exclusion Criteria: - being medically unstable (e.g., medical condition that requires frequent medical appointments or hospitalizations and interferes with ability to participate in study activities) - report active substance abuse or testing positive drug or alcohol use - taking bupropion, varenicline, nicotine replacement products and/or involved in any other smoking cessation treatment - participating in any treatment or activity that includes music as a focus - having a seizure disorder, other neurological illnesses, or a family history of seizures |
Country | Name | City | State |
---|---|---|---|
United States | New York University School of Medicine | New York | New York |
Lead Sponsor | Collaborator |
---|---|
NYU Langone Health |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Snaith-Hamilton Pleasure Scale (SHAPS) | Measures Pleasure Pre Music Session | 1 Day | |
Primary | Snaith-Hamilton Pleasure Scale (SHAPS) Post Music Session | Measures Pleasure Post Music Session | 1 Day | |
Primary | Pleasure Rating Scale (PRS) | Measures Pleasure Pre Music Session | 1 Day | |
Primary | Pleasure Rating Scale (PRS) Post Music Session | Measures Pleasure Post Music Session | 1 Day | |
Primary | Questionnaire of Smoking Urges-Brief (QSU-B) | Measures Cravings Pre Music Session | 1 Day | |
Primary | Questionnaire of Smoking Urges-Brief (QSU-B) Post Music Session | Measures Cravings Post Music Session | 1 Day | |
Primary | Minnesota Nicotine Withdrawal Scale (MNWS) | Measures Withdrawal Pre Music Session and Post Music Session | 1 Day | |
Primary | Minnesota Nicotine Withdrawal Scale (MNWS) Post Music Session | Measures Withdrawal Post Music Session | 1 Day |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05039489 -
A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT05321602 -
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 1 | |
Completed |
NCT05111548 -
Brain Stimulation and Cognitive Training - Efficacy
|
N/A | |
Completed |
NCT04503954 -
Efficacy of Chronic Disease Self-management Program in People With Schizophrenia
|
N/A | |
Completed |
NCT02831231 -
Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium
|
Phase 1 | |
Completed |
NCT05517460 -
The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center
|
N/A | |
Completed |
NCT03652974 -
Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy
|
Phase 4 | |
Recruiting |
NCT04012684 -
rTMS on Mismatch Negativity of Schizophrenia
|
N/A | |
Recruiting |
NCT04481217 -
Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT00212784 -
Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)
|
Phase 3 | |
Completed |
NCT04092686 -
A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
|
Phase 3 | |
Completed |
NCT01914393 -
Pediatric Open-Label Extension Study
|
Phase 3 | |
Recruiting |
NCT03790345 -
Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics
|
Phase 2/Phase 3 | |
Recruiting |
NCT05956327 -
Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training
|
N/A | |
Terminated |
NCT03209778 -
Involuntary Memories Investigation in Schizophrenia
|
N/A | |
Terminated |
NCT03261817 -
A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders
|
N/A | |
Completed |
NCT02905604 -
Magnetic Stimulation of the Brain in Schizophrenia or Depression
|
N/A | |
Recruiting |
NCT05542212 -
Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia
|
N/A | |
Completed |
NCT04411979 -
Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia
|
N/A | |
Terminated |
NCT03220438 -
TMS Enhancement of Visual Plasticity in Schizophrenia
|
N/A |